1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sanofi, Denali Drug Fails In ALS, Adding To RIPK1 Program Setbacks

Phase II Trial In Multiple Sclerosis Ongoing

 
• By Mandy Jackson

The companies have partnered on the development of RIPK1 inhibitors for multiple indications since 2018, but have yet to see success, having discontinued one of three drugs already.

Question mark made by white pills spilling out of brown glass bottle on pink background
It remains to be seen if RIPK1 inhibition will succeed in the clinic • Source: Shutterstock

Denali Therapeutics Inc. said on 16 February that SAR443820/DNL788, an oral brain-penetrant RIPK1 inhibitor co-developed with Sanofi, failed in the Phase II HIMALAYA clinical trial testing the drug in amyotrophic lateral sclerosis (ALS). The companies have moved three RIPK1 inhibitors into the clinic since entering into a collaboration in 2018 for which Sanofi paid Denali $125m up front, but they have yet to see success beyond Phase I for any of the drug candidates.

Key Takeaways

  • Denali said Sanofi’s Phase II trial of RIPK1 inhibitor SAR443820/DNL788 failed in a Phase II ALS trial, but a Phase II study in MS is ongoing.

South San Francisco-based Denali disclosed in a filing with the US Securities and Exchange Commission that, according to Sanofi, the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Where Next For Biologics In COPD After Roche’s Astegolimab Phase III Missfire?

 
• By Sushmita Panda

The Phase III failure could dent Roche’s hopes of entering the COPD market with its novel therapy, despite its success in a large Phase IIb trial. It also marks another disappointment for the anti-IL33/ST2 approach.

Abivax Over The Moon As Obefazimod Storms Phase III

 
• By Kevin Grogan

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place

 
• By Andrew McConaghie

Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.

Replimune CRL Could Hold Warning For Accelerated Approvals

 
• By Jessica Merrill

FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.

More from R&D

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

 
• By Dexter Jie Yan

Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.

Pharma Gets A Compatriot At CDER With Tidmarsh Appointment To Top Spot

 
• By Jessica Merrill

Drug manufacturers may find comfort in the appointment of former biotech CEO and entrepreneur George Tidmarsh to lead the FDA’s Center for Drug Evaluation and Research.